Haemate P/Humate-P: a systematic review

Thrombosis Research

Volumn 124, Issue SUPPL. 1, 2009, Pages

  Berntorp, Erik ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Factor VIII; Haemate P; Haemophilia A; Humate P; Von Willebrand disease; Von Willebrand factor

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; DESMOPRESSIN;

ANAPHYLAXIS; ARTICLE; BODY TEMPERATURE; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MARKETING; DRUG SAFETY; GOLD STANDARD; HEMOLYSIS; HEMOPHILIA; HEMOPHILIA A; HUMAN; HYPERVOLEMIA; IMMUNOLOGICAL TOLERANCE; LUNG EMBOLISM; PLASMA; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROPHYLAXIS; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; SIDE EFFECT; SUBSTITUTION THERAPY; THROMBOEMBOLISM; VIRUS TRANSMISSION; VON WILLEBRAND DISEASE;

ADULT; CHILD; COAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FACTOR VIII; HEMOPHILIA A; HUMANS; TREATMENT OUTCOME; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR;

EID: 71549152209     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(09)70152-5     Document Type: Article

References (21)

1. Schramm W. Haemate® P von Willebrand factor/factor VIII concentrate: 25 years of clinical experience. Haemophilia 14 Suppl 5 (2008) 3-10
2. Berntorp E., Archey W., Auerswald G., Federici A.B., Franchini M., Knaub S., et al. A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate® P/Humate-P®: history and clinical performance. Eur J Haematol 80 Suppl 70 (2008) 3-35
3. Budde U., Metzner H.J., and Müller H.G. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease. Semin Thromb Haemost 32 (2006) 626-635
4. Gill J.C., Ewenstein B.M., Thompson A.R., Mueller-Velten G., and Schwartz B.A. Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/VWF concentrate (Humate-P). Haemophilia 9 (2003) 688-695
5. Thompson A.R., Gill J.C., Ewenstein B.M., Mueller-Velten G., and Schwartz B.A. Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/VWF concentrate (Humate-P®). Haemophilia 10 (2004) 42-51
6. Lillicrap D., Poon M.C., Walker I., Xie F., and Schwartz B.A. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, Haemate P/Humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost 87 (2002) 224-230
7. Lethagen S., Berntorp E., and Nilsson I.M. Pharmacokinetics and hemostatic effect of different factor VIII/von Willebrand factor concentrates in von Willebrand's disease type III. Ann Hematol 65 (1992) 253-259
8. Mannucci P.M., Tenconi P.M., Castaman G., and Rodeghiero F. Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial. Blood 79 (1992) 3130-3137
9. Gill J.C. Von Willebrand factor/factor VIII (VWF/FVIII) concentrate is safe and effective for management of elective surgery in adults and children with von Willebrand disease (VWD): combined results of United States (US) and European (EU) studies. Blood 110 (2007) abstract 2142.
10. Lethagen S., Kyrle P.A., Castaman G., Haerte S., and Mannucci P.M. Von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery. J Thromb Haemost 5 (2007) 1420-1430
11. Gröner A. Pathogen safety of plasma-derived products - Haemate® P/Humate-P®. Haemophilia 14 Suppl 5 (2008) 54-71
12. Schimpf K., Mannucci P.M., Kreuz W., Brackmann H.H., Auerswald G., Ciavarella N., et al. Absence of hepatitis after treatment with a pasteurized factor VIII concentrate in patients with hemophilia and no previous transfusions. N Engl J Med 316 (1987) 918-922
13. Schimpf K., Brackmann H.H., Kreuz B., Haschke F., Schramm W., Moesseler J., et al. Absence of anti-human immunodeficiency virus types 1 and 2 seroconversion after the treatment of hemophilia A or von Willebrand's disease with pasteurized factor VIII concentrate. N Engl J Med 321 (1989) 1148-1152
14. Vey M., Wiegand T., Baron H., and Gröner A. Prion removal in the production of coagulation factor concentrate Humate-P from human plasma. Blood 98 (2001) Abstract 4096.
15. Schäfer W., Gnau O., Seyfert-Brandt W., Wiegand T., Vey M., Groschup M., et al. Removal of prions by the manufacturing process of the VWF/FVIII coagulation concentrate Haemate P/Humate-P. Haemophilia 12 Suppl 2 (2006) poster 042.
16. Makris M., Colvin B., Gupta V., Shields M.L., and Smith M.P. Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand's disease. Thromb Haemost 88 (2002) 387-388
17. Mannucci P.M. Venous thromboembolism in von Willebrand disease. Thromb Haemost 88 (2002) 378-379
18. Berntorp E., Ekman M., Gunnarsson M., and Nilsson I.M. Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations. Haemophilia 2 (1996) 95-99
19. Kreuz W., Ehrenforth S., Funk M., Auerswald G., Mentzer D., Joseph-Steiner J., et al. Immune tolerance therapy in paediatric haemophiliacs with factor VIII inhibitors: 14 years follow-up. Haemophilia 1 (1995) 24-32
20. Auerswald G., Spranger T., and Brackmann H.H. The role of plasma-derived factor III/von Willebrand factor concentrates in the treatment of hemophilia A patients. Haematologica 88 (2003) EREP05.
21. Suzuki T., Arai M., Amano K., Kagawa K., and Fukutake K. Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor. Thromb Haemost 76 (1996) 749-754